Switching to a protease inhibitor-containing, nucleoside-sparing regimen (lopinavir/ritonavir plus efavirenz) increases limb fat but raises serum lipid levels: Results of a prospective randomized trial (AIDS Clinical Trial Group 5125s)

Pablo Tebas, Jiameng Zhang, Kevin Yarasheski, Scott Evans, Margaret A. Fischl, Abby Shevitz, Judith Feinberg, Ann C. Collier, Cecilia Shikuma, Barbara Brizz, Fred Sattler

Research output: Contribution to journalArticlepeer-review

54 Scopus citations

Fingerprint Dive into the research topics of 'Switching to a protease inhibitor-containing, nucleoside-sparing regimen (lopinavir/ritonavir plus efavirenz) increases limb fat but raises serum lipid levels: Results of a prospective randomized trial (AIDS Clinical Trial Group 5125s)'. Together they form a unique fingerprint.

Medicine & Life Sciences